Revolutionizing Dry Eye Treatment: The Tixel i System
In an age where quick and effective medical treatments are paramount, Novoxel Inc. introduces the Tixel i system, which has recently received clearance from U.S. regulatory authorities for widespread use. This groundbreaking device represents a significant advancement in alleviating dry eye symptoms, notably for patients suffering from Meibomian Gland Dysfunction (MGD). The swift 2-minute treatment promises lasting results and relief for those struggling with these uncomfortable conditions.
Understanding Dry Eye and Its Impacts
Dry eye syndrome is a common yet often overlooked issue that can lead to significant discomfort and decreased quality of life. Many individuals experience symptoms ranging from dryness and irritation to redness and a gritty sensation in the eyes. The condition is usually caused by insufficient tear production or poor-quality tears, leading to inflammation and damage to the ocular surface. With millions affected globally, innovative treatments like the Tixel i become vital in managing this condition.
The Tixel i Treatment Explained
The Tixel i system utilizes a unique Thermo-Mechanical Action (TMA®) technology designed to apply targeted heat and pressure to the eyelids. This not only enhances the function of the meibomian glands but also facilitates greater lubricant distribution to the eye surface, thereby providing notable relief from dry eye symptoms. During the procedure, patients have reported a significant reduction in discomfort, and these improvements can extend for at least six months.
Patient Experience with Tixel i
According to Dr. Gregg J. Berdy, an ophthalmologist involved in the clinical research of the Tixel i, patients have shared overwhelmingly positive results post-treatment. Many describe their eyes feeling more moist during the procedure, with the simplicity of the treatment process being highlighted as a significant advantage. Not requiring anesthesia, coupling gels, or complex applicators, the Tixel i stands out as a user-friendly solution for both clinicians and patients.
Continuing Medical Innovation
Novoxel Inc.’s commitment to innovation is evident, having introduced not only the Tixel i but also the Tixel 2 system for aesthetic applications, which showcases their versatility in treatment offerings. The company emphasizes that the regimen involves only three brief sessions, spaced two weeks apart, allowing for a convenient treatment schedule. Of particular note is that, unlike many traditional treatments, the improvement in symptoms remains sustained even after the treatment course has concluded.
Local Manufacturing and Support
While the Tixel i systems are manufactured in advanced facilities in Germany and Israel, Novoxel Inc. has established a robust presence within the U.S. market. Their Tennessee facility is the hub for sales, marketing, and technical support, ensuring that patients and practitioners have immediate access to assistance and information regarding the Tixel product line.
About Novoxel Inc.
Founded in 2011, Novoxel Inc. is dedicated to scientific and clinical innovation designed to bring cutting-edge medical solutions to fruition. The company has secured numerous patents across various regions, highlighting its commitment to developing effective and non-invasive treatment tools. The Tixel family of products is crafted to deliver visible outcomes without the drawbacks of traditional methods such as extended downtime or reliance on expensive, single-use components.
Frequently Asked Questions
1. What is the Tixel i system?
The Tixel i system is a medical device developed by Novoxel Inc. that provides a 2-minute treatment for dry eye symptoms, particularly beneficial for patients with Meibomian Gland Dysfunction.
2. How does the Tixel i technology work?
It uses Thermo-Mechanical Action (TMA®), which applies localized heat and pressure to the eyelids, enhancing gland function and improving tear distribution.
3. How long do the effects of the treatment last?
Patients can experience relief for at least six months after undergoing the treatment regimen, involving three sessions spaced two weeks apart.
4. Is the Tixel i treatment safe?
Yes, the Tixel i treatment is designed to be safe and effective, being non-invasive and not requiring anesthesia or complicated setups.
5. Where is Novoxel Inc. based?
While Novoxel is an international company with manufacturing in Germany and Israel, it has established its operational base for sales and support in the USA, specifically in Tennessee.
